+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comparison of therapeutic effects between monotherapy and combination therapy of Lopinavir/Ritonavir and Arbidol in COVID-19

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Objective To compare the therapeutic effects and adverse drug reaction between monotherapy and combination therapy of Lopnavir / Ritonavir and Arbidol in coronavirus disease 2019 (COVID-19).

          Methods Retrospective analysis were conducted on 75 cases with common COVID-19,in Yongwu Hospital affiliated with the People′ s Hospital of Guangxi Zhuang Autonomous Region between February 16 and 26, 2020. According to medication history, patients were assigned into Lopnavir/Ritonavir combine with Arbidol-based therapy (Group A), Lopnavir/Ritonavir-based therapy (Group B), and Arbidol-based therapy (Group C). The three groups were compared in results of therapeutic effects, ratio of negative conversion in nucleic acid, absorption of pulmonary exudation and adverse drug reactions.

          Results The average age of the patients in the three groups was (42.68 ± 3.44) years old. The main symptoms of admission were fever (88.00%), cough (84.00%), sore throat (29.33%) and chest tightness (17.33%). There are no significant difference of related results of sex, age, basic disease, blood routine, liver function, kidney function, etc between three groups at the time of admission ( P>0.05); After intervention of treatment, the similarity has been showed in the three groups at the ratio of recovery(group A 94.28%, group B 86.21%, group C 90.91%), absorption of pulmonary exudation(group A 88.57%, group B 82.76%, group C 72.73%) and negative conversion in nucleic acid (group A: 48.57%, group B: 48.28%, group C: 54.55%) ( P>0.05); The diarrhea, nausea, bloating adverse drug reactions rate of group A and B were much more higher than that of group C (group A 88.57%, group B 82.76%, group C 18.18%), (group A 88.57%, group B 82.76%, group C 36.36%), (group A 88.57%, group B 82.76%, group C 36.36%)( P<0.05).

          Conclusion The monotherapy and combination therapy of Lopnavir/Ritonavir and Arbidol have achieved good therapeutic effects for COVID-19, while Lopnavir / Ritonavir has showed more adverse effects than Arbidol in clinical cases.


          摘要: 目的 分析比较洛匹那韦/利托那韦和阿比多尔及两者联合用药治疗新型冠状病毒肺炎疗效及药物不良反 应情况。 方法 回顾性分析 2020 年 2 月 16 日—2 月 26 日由广西各地转入广西壮族自治区人民医院邕武院区的 75 例普 通型新型冠状病毒肺炎患者临床资料,根据其用药史分成洛匹那韦/利托那韦联合阿比多尔治疗组(A 组)、洛匹那韦/利 托那韦治疗组(B 组)和阿比多尔治疗组(C 组),比较三组治疗前一般临床指标,治疗后各组药物的疗效、鼻咽拭子核酸 转阴率、肺部病灶吸收率、药物不良反应等情况。 结果 三组患者平均年龄(42.68±3.44)岁,入院症状主要表现为发热(88.00%)、咳嗽(84.00%)、咽痛(29.33%)和胸闷痛(17.33%);三组患者入院时性别、年龄、基础疾病、血常规、肝、肾功能 等一般情况比较差异均无统计学意义( P>0.05),治疗后相比,三组患者发病症状好转率(A 组 94.28%,B 组 86.21%,C 组 90.91%)、肺部病灶吸收率(A 组 88.57%,B 组 82.76%,C 组 72.73%)、鼻咽拭子核酸转阴率(A 组 48.57%,B 组 48.28%,C 组 54.55%)差异无统计学意义( P>0.05);A 组、B 组患者出现腹泻、恶心、腹胀等药物不良反应症状率显著高于 C 组患者(A 组 88.57%,B 组 82.76%,C 组 18.18%)(A 组 88.57%,B 组 82.76%,C 组 36.36%)(A 组 88.57%,B 组 82.76%,C 组36.36%)( P<0.0167)。 结论 洛匹那韦/利托那韦和阿比多尔及两者联合用药三种治疗方案用于治疗新型冠状病毒肺 炎均取得良好疗效,但临床上洛匹那韦/利托那韦较阿比多尔出现较多药物不良反应

          Related collections

          Author and article information

          China Tropical Medicine
          China Tropical Medicine (China )
          01 October 2020
          01 October 2020
          : 20
          : 10
          : 972-975
          1Emergency Department, The Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530021,China
          2Scientific Research Department, The Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530021,China
          Author notes
          *Corresponding author: LYU Liwen, E-mail: iculvliwen@
          © 2020 Editorial Department of China Tropical Medicine

          This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See

          Self URI (journal page):
          Journal Article


          Comment on this article